Pfizer Shares Decline Amid CFO Transition Concerns Over Leadership Continuity
Pfizer (NYSE:PFE) shares fell by 2.74% following the announcement that its CFO, Dave Denton, will leave in August and be replaced on an interim basis by Cecile Guegan. The transition has raised concerns about leadership continuity and execution of Pfizer's 2026 guidance amid patent expirations and cost-control efforts.
Topics: 2026 guidance CFO transition leadership change Pfizer stock decline